Validation of two immunoassays for oxytocin measurements in human saliva

PLoS One. 2024 Apr 18;19(4):e0297539. doi: 10.1371/journal.pone.0297539. eCollection 2024.

Abstract

The objective of this research was to develop and validate two immunoassays for oxytocin measurement in human saliva, one using a monoclonal and the other a polyclonal antibody against oxytocin, whose affinity for oxytocin was tested by an antibody mapping epitope analysis. These assays were analytically validated and used to compare oxytocin concentrations with those obtained with a commercial kit before and after the extraction or reduction/alkylation (R/A) treatments to saliva samples. The assays were also used to evaluate changes in salivary oxytocin concentrations following a physical effort and an induced psychological stress, which have previously been described as situations that cause an increase in salivary oxytocin. Both assays showed to be precise and accurate in the validation studies, and the antibodies used showed a defined binding region in case of the monoclonal antibody, whereas the polyclonal antibody showed binding events through all the oxytocin sequence. Although the monoclonal and polyclonal assays showed a positive correlation, they give results in a different range of magnitude. Both assays showed significant increases in oxytocin concentrations when applied after the physical effort and the psychological stress. This study shows that a variability in the reported values of oxytocin can occur depending on the assay and indicates that the use of different types of antibodies can give a different range of values when measuring oxytocin in saliva.

MeSH terms

  • Antibodies, Monoclonal / metabolism
  • Biological Assay
  • Humans
  • Immunoassay
  • Oxytocin* / metabolism
  • Saliva* / metabolism

Substances

  • Oxytocin
  • Antibodies, Monoclonal

Grants and funding

This research was funded by ‘MINECO (Spain), FEDER funds (EU)’ (AGL2016-79096-R) and by the Spanish “Agencia Estatal de investigación” (Grant Reference PDC2021-121291-I00 / AEI) and the European Union – NextGenerationEU. M. López-Arjona was founded by ‘MECD’ (Spain) (FPU16/02170) and ‘Spanish Ministry of Science and Innovation’ (FJC2021-047105-I) (Spain). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.